Clinical Trials
GDC-6036 in combination w/other anti-cancer therapies in untreated metastatic NSCLC w/KRAS G12C mut
Disease Type: Lung
A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville